Medical Devices

Nanjing Seidus Biotechnology Co., LTD.

• Yongyang Street “Seidus Biotechnology Co., Ltd. is mainly engaged in the research and development, production and sales of medical devices for implant intervention biomaterials.
• Relying on a mature scientific research team and adhering to independent innovation, the company has broken through and mastered a number of key core technologies and production processes.
• In the field of hemostasis and surgical anti-adhesion, tissue sealing and protection, interventional embolization, tissue engineering and other biological materials with leading technology, some products to achieve “domestic first”, is a domestic leader in the subdivision industry.
• Represented by composite microporous polyglycan styptic powder and surgical anti-adhesion liquid, the company has strong technological leadership and scientific research advantages in the field of hemostasis and surgical anti-adhesion. T
• he company’s composite microporous polychitosan styptic powder has been widely used in trauma surgery in the fields of surgery, obstetrics and gynecology, orthopedics, urology, burn and other fields. The product generates “instant gel” through hydrophilic molecular siophysios, mechanically seals the blood vessel rupture, stimulates and strengthens the endogenous coagulation mechanism, shorens the coagulation time, and is the only compound starch absorbable hemostatic product in China.
• Have a strong level of scientific research; Another product, surgical anti-adhesion liquid, was identified as “national key new product”. As an industry model of surgical anti-adhesion liquid products, the company was invited by the China Institute of Food and Drug Control to participate in the formulation of national standards for chitin sugar products.

Medical equipment, first aid series.